81 related articles for article (PubMed ID: 7032940)
1. Hydroxy-9-methyl-2-Ellipticinium (NSC 264-137) in 52 cases of osseous metastases from breast cancer.
Juret P; Le Talaer Y; Couette JE; Delozier T
Eur J Cancer (1965); 1980; Suppl 1():277-9. PubMed ID: 7032940
[No Abstract] [Full Text] [Related]
2. [Hydroxy-9-methyl-2-ellipticinium (NSC 264-137) for osseous metastases from breast cancer. A 4 year experience (author's transl)].
Juret P; Couette JE; Delozier T; Le Talaer JY
Bull Cancer; 1981; 68(3):224-31. PubMed ID: 7039729
[TBL] [Abstract][Full Text] [Related]
3. Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5-year experience.
Juret P; Heron JF; Couette JE; Delozier T; Le Talaer JY
Cancer Treat Rep; 1982 Nov; 66(11):1909-16. PubMed ID: 7139636
[TBL] [Abstract][Full Text] [Related]
4. [Hydroxy 9-methyl 2-ellipticinium acetate (NSC 264-137). Toxicologic study and therapeutic effect in 100 cancers (author's transl)].
Juret P; Tanguy A; Girard A; Le Talaer JY; Abbatucci JS; Dat-Yuong ; Le Pecq JB; Paoletti C
Nouv Presse Med; 1979 Apr; 8(18):1495-8. PubMed ID: 471724
[TBL] [Abstract][Full Text] [Related]
5. [Renal toxicity of 9-hydroxy-2-methyl-ellipticinium].
Ryckelynck JP; Heron JF; Juret P; Schneider P; Herlin P; De Ranieri E; Hardouin A; Peny J; Le Talaer JY
Nephrologie; 1984; 5(2):59-63. PubMed ID: 6483073
[TBL] [Abstract][Full Text] [Related]
6. [2 N methyl 9 hydroxy-ellipticine in treatment of metastatic breast cancers (author's transl)].
Rouëssé J; Huertas D; Sancho-Garnier H; Le Chevalier T; Amiel JL; Brulé G; Tursz T; Mondésir JM
Bull Cancer; 1981; 68(5):437-41. PubMed ID: 7037078
[TBL] [Abstract][Full Text] [Related]
7. [N-Methyl-9 hydroxy-ellipticine (NSC 264-137) in the treatment of malignant metastases. Preliminary results (author's transl)].
Rouesse J; Tursz T; Le Chevalier T; Huertas D; Amiel JL; Brule G; Callet B; Droz JP; Voisin PM; Sancho-Garnier H; Le Pecq JB; Paoletti C
Nouv Presse Med; 1981 May; 10(24):1997-9. PubMed ID: 7255136
[TBL] [Abstract][Full Text] [Related]
8. Preliminary trial of 9-hydroxy-2-methyl ellipticinium (NSC 264--137) in advanced human cancers.
Juret P; Tanguy A; Girard A; Le Talaer JY; Abbatucci JS; Dat-Xuong N; Le Pecq JB; Paoletti C
Eur J Cancer (1965); 1978 Feb; 14(2):205-6. PubMed ID: 342255
[No Abstract] [Full Text] [Related]
9. Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast.
Sternberg CN; Yagoda A; Casper E; Scoppetuolo M; Scher HI
Anticancer Res; 1985; 5(4):415-7. PubMed ID: 4037737
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung. EORTC Lung Cancer Cooperative Group.
Anderson G; Clavel M; Smyth J; Giaccone G; Gracia M; Planting AS; Dalesio O; Kirkpatrick A; McVie G
Eur J Cancer Clin Oncol; 1989 May; 25(5):909-10. PubMed ID: 2737223
[No Abstract] [Full Text] [Related]
11. Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137).
Paoletti C; Le Pecq JB; Dat-Xuong N; Juret P; Garnier H; Amiel JL; Rouesse J
Recent Results Cancer Res; 1980; 74():107-23. PubMed ID: 7003658
[TBL] [Abstract][Full Text] [Related]
12. [2 new antineoplastic derivatives: 9-hydroxy-2-methyl-ellipticinium (acetate) and 9-hydroxy-2,6-dimethyl-ellipticinium (chloride). Effect on mouse L 1210 leukemia].
Le Pecq JB; Gosse C; Nguyen-Dat-Xuong ; Paoletti C
C R Acad Hebd Seances Acad Sci D; 1975 Nov; 281(18):1365-7. PubMed ID: 815025
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates in breast cancer patients with skeletal metastases.
Shapiro CL
Hematol Oncol Clin North Am; 1994 Feb; 8(1):153-63. PubMed ID: 8150777
[TBL] [Abstract][Full Text] [Related]
14. [The role of adjuvant clodronate therapy for prevention of bone metastasis in breast cancer].
Horváth Z
Magy Onkol; 2002; 46(4):361-4. PubMed ID: 12563361
[TBL] [Abstract][Full Text] [Related]
15. [Letter: L. Dopa and bone metastases in breast cancer].
Ghozian D; Amor B; Delbarre F
Nouv Presse Med; 1974 Mar; 3(11):678. PubMed ID: 4599794
[No Abstract] [Full Text] [Related]
16. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
17. [Double-blind trial of oral clodronate in breast cancer patients with bone metastases].
Paterson AH; Powles TJ; Kanis JA; McCloskey E; Hanson J; Ashley S
Bull Cancer; 1993; 80(10 Suppl):50-6. PubMed ID: 8081032
[No Abstract] [Full Text] [Related]
18. The role of bisphosphonates in breast cancer.
Coleman RE
Breast; 2004 Dec; 13 Suppl 1():S19-28. PubMed ID: 15585379
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy of bone metastases in breast cancer patients.
Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic value of whole-body MRI and bone scintigraphy in the detection of osseous metastases in patients with breast cancer--A Prospective Double-Blinded Study at two Hospital Centers].
Ohlmann-Knafo S; Kirschbaum M; Fenzl G; Pickuth D
Rofo; 2009 Mar; 181(3):255-63. PubMed ID: 19229791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
